ADMA Biologics, Inc. vs Novavax, Inc.: SG&A Expense Trends

SG&A Expense Trends: ADMA Biologics, Inc. vs Novavax, Inc.

In the ever-evolving biotech industry, understanding financial trends is crucial. Over the past decade, ADMA Biologics, Inc. and Novavax, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, ADMA Biologics saw a steady increase in SG&A expenses, growing by over 1,100%. This reflects their strategic investments in operational expansion and market penetration. Meanwhile, Novavax, Inc. experienced a dramatic surge, particularly from 2020 onwards, with expenses skyrocketing by over 2,200%. This spike aligns with their aggressive push in vaccine development during the global pandemic. By 2023, Novavax's SG&A expenses were nearly eight times higher than ADMA's, highlighting their expansive operational scale. These trends underscore the dynamic nature of biotech financial strategies, where companies balance growth with operational costs to maintain competitive edges.